Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions (MRX34-102)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02862145 |
Recruitment Status :
Withdrawn
(5 immune related serious adverse events in Phase 1 study)
First Posted : August 10, 2016
Last Update Posted : September 27, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma | Drug: MRX34 Drug: Dexamethasone | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions |
Study Start Date : | August 2016 |
Estimated Primary Completion Date : | September 2017 |
Estimated Study Completion Date : | December 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment with MRX34
Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
|
Drug: MRX34
Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
Other Name: miR-Rx34 Drug: Dexamethasone Premedication during the week of treatment
Other Name: Decadron |
- Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing and drug concentration in tissue biopsies [ Time Frame: 3 months ]
- Frequency and severity of adverse events associated with MRX34 treatment [ Time Frame: 6 months ]
- Change in tumor measurements over time using RECIST criteria. [ Time Frame: 6 months ]
- RNA sequencing analysis of PBMCs to evaluate gene expression through TLR signaling, RIG-I Pathway and PD1/PD-L1 Blockade. [ Time Frame: During 3 months of treatment ]
- Assessment of MRX34 accumulation in tumor tissue measured by qPCR and CISH. [ Time Frame: During 3 months of treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 95 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ≥18 years of age
- Advanced or metastatic cutaneous, acral or mucosal melanoma
- Tumor lesions accessible to serial biopsies
- ECOG ≤ 1
- ANC ≥, Plts ≥100,000 /mm3
Exclusion Criteria:
- Serious active non-malignant disease
- Central Nervous System metastasis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02862145
Study Director: | Susan Smith, MSN | Mirna Therapeutics |
Responsible Party: | Mirna Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT02862145 |
Other Study ID Numbers: |
MRX34-102 |
First Posted: | August 10, 2016 Key Record Dates |
Last Update Posted: | September 27, 2016 |
Last Verified: | July 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Biosy accessible melanoma |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Neoplasms by Site Skin Diseases Dexamethasone |
Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents |